[go: up one dir, main page]

AR099228A1 - Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos - Google Patents

Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos

Info

Publication number
AR099228A1
AR099228A1 ARP150100295A ARP150100295A AR099228A1 AR 099228 A1 AR099228 A1 AR 099228A1 AR P150100295 A ARP150100295 A AR P150100295A AR P150100295 A ARP150100295 A AR P150100295A AR 099228 A1 AR099228 A1 AR 099228A1
Authority
AR
Argentina
Prior art keywords
independently selected
alkyl
fxia
och3
haloalkyl
Prior art date
Application number
ARP150100295A
Other languages
English (en)
Inventor
J Orwat Michael
R Wexler Ruth
J Pinto Donald
R Corte James
Dlucca Indawati
Fang Tianan
Yang Wu
Wang Yufeng
K Dilger Andrew
Balashanmuga Pabbisetty Kumar
R Ewing William
Zhu Yeheng
m smith ii Leon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR099228A1 publication Critical patent/AR099228A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Estos compuestos son inhibidores selectivos del factor Xla o inhibidores duales de FXIa y calicreína plasmática. También, composiciones farmacéuticas que comprenden estos compuestos y su uso para tratar trastornos tromboembólicos y/o inflamatorios. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o un estereoisómero, un tautómero o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde: - - - es un enlace opcional; el anillo A se selecciona independientemente del grupo de fórmulas (2); B se selecciona independientemente de CH, N, NR³; siempre que B sea NR³, el otro R³ está ausente; R¹ se selecciona independientemente de H, F, C₁₋₄ alquilo, alcoxi e hidroxilo; R² se selecciona independientemente de H y F; R³, en cada caso, se selecciona independientemente de H, C₁₋₄ alquilo, C₁₋₄ haloalquilo, -(CH₂)ₙ-OR⁵, -(CH₂)ₙ-C(O)OR⁵, C₃₋₆ cicloalquilo opcionalmente sustituido con halógeno, y heteroarilo de 6 miembros que comprende átomos de carbono y 1 - 2 átomos de nitrógeno, y opcionalmente sustituido con OH; R⁴ se selecciona independientemente de H, OH, F, OC₁₋₄ alquilo, C₁₋₄ alquilo y CN; R⁵ se selecciona independientemente de H y C₁₋₄ alquilo; R⁶ se selecciona independientemente H, F, Cl, Br, CN, OCH₃, CH₃, C(O)CH₃, CHF₂ CCH₃F₂, CF₃, OCHF₂, NHC(O)C₁₋₄ alquilo, C₃₋₆ cicloalquilo y heterociclo sustituido con R⁹ de 5 miembros; R⁷ se selecciona independientemente de H y F; R⁸ se selecciona independientemente de H, F, Cl y OCH₃; R⁹ se selecciona independientemente de H, C₁₋₄ alquilo, haloalquilo y halógeno; y n, en cada caso, es un entero seleccionado independientemente de 0, 1 y 2.
ARP150100295A 2014-01-31 2015-01-30 Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos AR099228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461933948P 2014-01-31 2014-01-31

Publications (1)

Publication Number Publication Date
AR099228A1 true AR099228A1 (es) 2016-07-06

Family

ID=52484569

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100295A AR099228A1 (es) 2014-01-31 2015-01-30 Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos

Country Status (24)

Country Link
US (3) US20170057961A1 (es)
EP (1) EP3099688B1 (es)
JP (1) JP6419836B2 (es)
CN (1) CN106459051B (es)
AR (1) AR099228A1 (es)
BR (1) BR112016016741B1 (es)
CA (1) CA2937738C (es)
CY (1) CY1120534T1 (es)
DK (1) DK3099688T3 (es)
EA (1) EA032650B1 (es)
ES (1) ES2655540T3 (es)
HR (1) HRP20172002T1 (es)
HU (1) HUE038060T2 (es)
LT (1) LT3099688T (es)
MX (1) MX2016009385A (es)
NO (1) NO2760821T3 (es)
PL (1) PL3099688T3 (es)
PT (1) PT3099688T (es)
RS (1) RS56785B1 (es)
SI (1) SI3099688T1 (es)
SM (1) SMT201800024T1 (es)
TW (1) TWI703144B (es)
UY (1) UY35972A (es)
WO (1) WO2015116882A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141825A1 (es) 2011-10-14 2014-11-29 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
CN105228996B (zh) 2013-03-25 2017-11-28 百时美施贵宝公司 作为因子XIa抑制剂的含取代唑类的四氢异喹啉
NO2760821T3 (es) 2014-01-31 2018-03-10
CN110845498B (zh) 2014-01-31 2023-02-17 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
NO2721243T3 (es) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
ES2762987T3 (es) 2015-06-19 2020-05-26 Bristol Myers Squibb Co Macrociclos de diamida como inhibidores del factor XIA
US10676477B2 (en) 2015-07-29 2020-06-09 Bristol-Myers Squibb Company Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
KR102086934B1 (ko) * 2015-07-29 2020-03-09 브리스톨-마이어스 스큅 컴퍼니 알킬 또는 시클로알킬 P2' 모이어티를 갖는 인자 XIa 마크로시클릭 억제제
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
CA2998902C (en) * 2015-10-29 2024-03-26 Merck Sharp & Dohme Corp. Macrocyclic compounds as factor xia inhibitors
US10752641B2 (en) 2016-03-02 2020-08-25 Bristol-Myers Squibb Company Diamide macrocycles having factor XIa inhibiting activity
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑
BR112019010511A2 (pt) 2016-11-23 2019-09-17 Bayer Ag derivados de heterociclo bicíclico fundido como pesticidas
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
ES2867600T3 (es) 2017-01-10 2021-10-20 Bayer Ag Derivados de imidazol como pesticidas
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
CN110922412A (zh) * 2018-09-20 2020-03-27 复旦大学 具有抗精神病作用药物化合物的不对称合成方法
US12018027B2 (en) 2019-04-16 2024-06-25 China Resources Biopharmaceutical Company Limited Macrocyclic derivatives acting as XIa factor inhibitor
CN114341714A (zh) * 2019-07-08 2022-04-12 加里夏普创新有限责任公司 具有高对比度的紧凑型基于偏振的准直器
WO2021013209A1 (zh) * 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CN115215867B (zh) * 2021-04-21 2023-12-26 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途
WO2025002297A1 (zh) * 2023-06-30 2025-01-02 深圳信立泰药业股份有限公司 一种多取代的大环化合物及其制备方法与应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (fr) 1967-03-29 1968-05-17 Roussel Uclaf Nouvelles pénicillines et procédé de préparation
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249617A1 (en) 1996-04-03 1997-10-09 S. Jane Desolms Inhibitors of farnesyl-protein transferase
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
WO1999047545A2 (en) 1998-03-19 1999-09-23 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
GEP20033093B (en) 1998-05-26 2003-10-27 Warner Lambert Co Bicyclic Pyrimidines and Bicyclic 3,4-Dihydropyrimidines as Inhibitors of Cellular Proliferation, Compositions Containing Them and Methods for Treating Cell Proliferative Disorders
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
CZ20012379A3 (cs) 1999-01-02 2001-09-12 Aventis Pharma Deutschland Gmbh Nové deriváty malonové kyseliny, způsoby jejich přípravy, použití a farmaceutické přípravky obsahující tyto deriváty (inhibitory aktivity faktoru Xa)
AU4111700A (en) 1999-04-09 2000-11-14 Basf Aktiengesellschaft Low-molecular inhibitors of complement proteases
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
HU228195B1 (hu) 2001-09-21 2013-01-28 Bristol Myers Squibb Co Pirazolo-piridin gyûrût tartalmazó laktámok és származékaik, valamint az ezeket tartalmazó Xa faktor gátlására szolgáló gyógyszerkészítmények
WO2003041641A2 (en) 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003106438A1 (en) 2002-06-18 2003-12-24 The Scripps Research Institute Synthesis of diazonamide "a" core
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｘｉａ因子阻害剤としての置換ビアリール化合物
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
US20070111947A1 (en) 2005-10-14 2007-05-17 Mcmurry Thomas J Fibrin targeted therapeutics
KR20080067697A (ko) 2005-11-11 2008-07-21 에프. 호프만-라 로슈 아게 응고 인자 ｘａ의 억제제로서 카보사이클릭 융합된사이클릭 아민
ATE511502T1 (de) 2005-12-14 2011-06-15 Bristol Myers Squibb Co Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
TW200745062A (en) 2005-12-23 2007-12-16 Bristol Myers Squibb Co Macrocyclic factor VIIA inhibitors useful as anticoagulants
JP5342450B2 (ja) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
PE20091002A1 (es) 2007-06-13 2009-07-15 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8513433B2 (en) 2009-07-02 2013-08-20 Angion Biomedica Corp. Small molecule inhibitors of PARP activity
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
KR101901545B1 (ko) * 2010-02-11 2018-09-21 브리스톨-마이어스 스큅 컴퍼니 인자 ＸＩａ 억제제로서의 마크로사이클
WO2013009527A2 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
ES2572908T3 (es) 2011-10-14 2016-06-03 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
PE20141825A1 (es) 2011-10-14 2014-11-29 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
EP2766347B1 (en) 2011-10-14 2016-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
US9732085B2 (en) 2011-12-21 2017-08-15 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor Xia
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
KR102060376B1 (ko) 2012-05-10 2019-12-30 바이엘 파마 악티엔게젤샤프트 응고 인자 xi 및/또는 그의 활성화 형태 인자 xia에 결합할 수 있는 항체 및 그의 용도
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
JP6220786B2 (ja) 2012-07-19 2017-10-25 大日本住友製薬株式会社 １−（シクロアルキルカルボニル）プロリン誘導体
KR20150038369A (ko) * 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
KR20150038372A (ko) * 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
TR201807316T4 (tr) 2012-10-12 2018-06-21 Squibb Bristol Myers Co Bir faktör XIa inhibitörünün kristalli formları.
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9708308B2 (en) 2012-12-19 2017-07-18 Merck Sharp Dohme Corp. Factor IXa inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
CN105228996B (zh) 2013-03-25 2017-11-28 百时美施贵宝公司 作为因子XIa抑制剂的含取代唑类的四氢异喹啉
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
ES2633248T3 (es) 2013-07-23 2017-09-20 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos y su uso como factor XIa e inhibidores de calicreína plasmática
AR097755A1 (es) 2013-09-26 2016-04-13 Bayer Pharma AG Derivados sustituidos de fenilalanina como moduladores del factor xia
UY35745A (es) 2013-09-26 2015-04-30 Bayer Pharma AG Derivados sustituidos de fenilalanina
EP3049410A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate als faktor xia modulatoren
WO2015044170A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
CN105745192A (zh) 2013-09-26 2016-07-06 拜耳制药股份公司 取代的苯丙氨酸衍生物
WO2015044172A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
EP3049394A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate als faktor xia modulatoren
US20160237067A1 (en) 2013-09-26 2016-08-18 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
US20160229839A1 (en) 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
US20160257668A1 (en) 2013-10-07 2016-09-08 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
JP6337750B2 (ja) 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
US9718840B2 (en) 2014-01-14 2017-08-01 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
CN110845498B (zh) 2014-01-31 2023-02-17 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
NO2760821T3 (es) 2014-01-31 2018-03-10
CA2938884C (en) 2014-02-07 2024-02-13 eXIthera Pharmaceuticals Inc. Substituted azetidine compounds and their use as factor xia or kallikrein inhibitors
WO2015123091A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9944643B2 (en) 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9663527B2 (en) 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2015120777A1 (zh) 2014-02-14 2015-08-20 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
MX2016011468A (es) 2014-03-07 2017-01-23 Biocryst Pharm Inc Inhibidores de calicreína plasmática humana.
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9808445B2 (en) 2014-04-16 2017-11-07 Merck Sharp & Dohme Corp. Factor IXa inhibitors
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
AU2015267305A1 (en) 2014-05-28 2016-11-03 Merck Sharp And Dohme Corp. Factor XIa inhibitors
EP3197891B1 (de) 2014-09-24 2018-11-21 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
NO2721243T3 (es) 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
AU2015362422B2 (en) 2014-12-10 2019-11-14 Ono Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
ES2762987T3 (es) 2015-06-19 2020-05-26 Bristol Myers Squibb Co Macrociclos de diamida como inhibidores del factor XIA

Also Published As

Publication number Publication date
NO2760821T3 (es) 2018-03-10
EA032650B1 (ru) 2019-06-28
CN106459051B (zh) 2018-10-16
BR112016016741A2 (es) 2017-08-08
JP6419836B2 (ja) 2018-11-07
CA2937738C (en) 2023-01-17
PT3099688T (pt) 2018-01-15
SI3099688T1 (sl) 2017-12-29
EP3099688B1 (en) 2017-10-18
US20170057961A1 (en) 2017-03-02
BR112016016741B1 (pt) 2023-01-17
EA201691561A1 (ru) 2017-01-30
CN106459051A (zh) 2017-02-22
TW201615640A (zh) 2016-05-01
EP3099688A1 (en) 2016-12-07
HUE038060T2 (hu) 2018-09-28
US20170342071A1 (en) 2017-11-30
WO2015116882A1 (en) 2015-08-06
US10273236B2 (en) 2019-04-30
SMT201800024T1 (it) 2018-03-08
UY35972A (es) 2015-07-31
LT3099688T (lt) 2017-12-27
DK3099688T3 (en) 2018-01-15
HRP20172002T1 (hr) 2018-02-09
PL3099688T3 (pl) 2018-03-30
US20180222907A1 (en) 2018-08-09
RS56785B1 (sr) 2018-04-30
CY1120534T1 (el) 2019-07-10
TWI703144B (zh) 2020-09-01
ES2655540T3 (es) 2018-02-20
MX2016009385A (es) 2016-09-16
CA2937738A1 (en) 2015-08-06
JP2017504640A (ja) 2017-02-09

Similar Documents

Publication Publication Date Title
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR101208A1 (es) Espirocicloheptanos como inhibidores de rock
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR099788A1 (es) Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR106138A1 (es) Compuestos y métodos para inhibir jak
AR090847A1 (es) Compuestos moduladores del receptor huerfano retinoideo (ror)
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR108906A1 (es) Heterociclos de biarilmetilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure